COMMUNIQUÉS West-GlobeNewswire

RAD 202 Receives Approval to Start Phase 1 Therapeutic Trial

20/12/2024 - 14:00

Ethics approval received in Australia for the initiation of RAD’s Phase 1 therapeutic trial of 177 Lu-RAD202 in Breast and Gastric Cancers The Phase 1 First-In-Human study is designed to assess the safety, tolerability [...]

Commure Acquires Memora Health, a Digital Care Navigation Platform, to Enhance Intelligent Care Navigation

20/12/2024 - 14:00

MOUNTAIN VIEW, Calif., Dec. 20, 2024 (GLOBE NEWSWIRE) -- Commure, a leading healthcare technology company, announced today the acquisition of Memora Health (Memora), a digital care navigation platform. Memora will [...]

Apollomics Announces Top-line Results for Phase 3 Bridging Trial of Uproleselan in China in Patients with Relapsed or Refractory Acute Myeloid Leukemia

20/12/2024 - 14:00

FOSTER CITY, Calif., Dec. 20, 2024 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM) (“Apollomics” or the “Company”), a late-stage clinical biopharmaceutical company developing multiple oncology drug candidates to [...]

Alignment Healthcare to Present at the 43rd Annual J.P. Morgan Healthcare Conference

20/12/2024 - 14:00

ORANGE, Calif. , Dec. 20, 2024 (GLOBE NEWSWIRE) -- Alignment Healthcare, Inc. (NASDAQ: ALHC), today announced that it will present at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco on Wednesday, Jan [...]

IO Biotech secures up to €57.5 million in debt financing from the European Investment Bank

20/12/2024 - 14:05

Funds expected to be used to advance IO Biotech’s immune-modulating therapeutic cancer vaccines, including potential BLA submission for IO102-IO103 in 2025 Commitment is part of the European Investment Bank’s strategy [...]

Light-it Group Launches Enlighten Ventures: A Micro-VC Initiative to Propel Healthtech Innovation

20/12/2024 - 14:35

Javier Lempert (CTO & Founder), Alan Brande (CEO & Founder) and Martin Oppenheimer (COO & Founder) at Light-it’s HQ. AVENTURA, Fla., Dec. 20, 2024 (GLOBE NEWSWIRE) -- Light-it Group, a leading innovator in [...]

HWH International Inc. and Sharing Services Global Corporation see opportunity in Robotics

20/12/2024 - 15:00

BETHESDA, MD, Dec. 20, 2024 (GLOBE NEWSWIRE) -- HWH International Inc. (“HWH”) (Nasdaq: HWH) and its partner Sharing Services Global Corporation (“SHRG”) (OTC: SHRG) are taking further steps in their collaboration in [...]

Renovaro Enters into a Strategic Collaboration with Nebul to Advance a Paradigm Shift for Early Disease Detection

20/12/2024 - 15:00

Renovaro will Establish the GEDi CUBE Next Generation Nvidia Blackwell Cluster with Nebul's certified AI Healthcare Cloud solutions LOS ANGELES, Dec. 20, 2024 (GLOBE NEWSWIRE) -- Renovaro Inc. (NASDAQ: RENB) , a pioneer [...]

BioAtla, Inc. Announces Registered Direct Offering to Advance Two Mid-Stage Clinical Programs to Key Inflection Points

20/12/2024 - 15:00

SAN DIEGO, Dec. 20, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB) , a global clinical-stage biotechnology company (“BioAtla” or the “Company”) focused on the development of Conditionally Active Biologic (CAB) [...]

Channel Therapeutics Highlights Differences Between NaV1.7 and NaV1.8 in Light of Recent Clinical Data on Suzetrigine

20/12/2024 - 15:00

FREEHOLD, N.J., Dec. 20, 2024 (GLOBE NEWSWIRE) -- Channel Therapeutics Corporation, (“Channel” or the “Company”), (NYSE American: CHRO), a pioneer in the development of non-opioid pain treatment therapeutics, is [...]

Monopar Therapeutics Inc. Announces Pricing of $40 Million Public Offering of Common Stock and Concurrent Private Placement of Pre-Funded Warrants

20/12/2024 - 15:00

WILMETTE, Ill., Dec. 20, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR) (“Monopar” or the “Company”) , a clinical-stage biotechnology company focused on developing innovative treatments for patients [...]

NHS England Rolls Out Evkeeza® ▼(evinacumab) for Eligible Adults and Adolescents Aged 12 Years and Older with Homozygous Familial Hypercholesterolaemia (HoFH)

20/12/2024 - 09:00

INTENDED FOR USE WITH MEDICAL MEDIA IN THE UK ONLY LONDON, Dec. 20, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialisation of [...]

CancerVax Passes First Test with Flying Colors

20/12/2024 - 09:01

Recent in-vitro lab results confirm that the Company’s Smart mRNA can be used as a potential on/off switch for selectively detecting cancer cells Lehi, Utah, Dec. 20, 2024 (GLOBE NEWSWIRE) -- CancerVax Passes First Test [...]

Nxera Pharma to Present at the 43rd Annual J.P. Morgan Healthcare Conference

20/12/2024 - 09:30

Tokyo, Japan and Cambridge, UK, 20 December 2024 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) – formerly known as Sosei Group or Sosei Heptares – announces that Chris Cargill, President and CEO, will [...]

Cytokinetics Announces Sanofi Acquired Rights to Develop and Commercialize Aficamten in Greater China

20/12/2024 - 06:00

SOUTH SAN FRANCISCO, Calif., Dec. 20, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that Sanofi will acquire exclusive rights to develop and commercialize aficamten from Corxel [...]

Santhera Announces Approval in Hong Kong for AGAMREE® (Vamorolone) as a Treatment for Duchenne Muscular Dystrophy

20/12/2024 - 07:00

Department of Health (DoH) of Hong Kong approved AGAMREE® for the treatment of Duchenne muscular dystrophy (DMD) in patients aged 4 years and older Follows recent approval from China’s National Medical Products [...]

Idorsia provides update on the exclusive negotiations for the global rights to aprocitentan

20/12/2024 - 07:00

Ad hoc announcement pursuant to Art. 53 LR Company announces delay to the targeted timeline for signing a binding agreement Company in discussions with bondholders to restructure the company’s outstanding debt and [...]

Safe group annonce ses résultats du premier semestre 2024

20/12/2024 - 08:00

Note : - Compte tenu de la non-publication de comptes consolidés semestriels 2023, la comparabilité des données financières consolidées publiées au 30 juin 2024 a été effectuée avec les données financières consolidées [...]

Humacyte Announces FDA Approval of SYMVESS™ (acellular tissue engineered vessel-tyod) for the Treatment of Extremity Vascular Trauma

20/12/2024 - 04:47

– SYMVESS is a first-in-class bioengineered human tissue designed to be a universally implantable vascular conduit for use in arterial replacement and repair – – In clinical testing SYMVESS was observed to have high [...]